Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 31;12(11):3774.
doi: 10.3390/jcm12113774.

Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)

Israel Manzanedo  1   2   3 , Fernando Pereira  1   2   3 , Pedro Cascales-Campos  3   4 , Cristobal Muñoz-Casares  3   5 , Enrique Asensio  3   6 , Juan Torres-Melero  3   7 , Arancha Prada-Villaverde  3   8 , Ibán Caravaca-García  3   9 , Alberto Gutiérrez-Calvo  3   10 , Javier Vaqué  3   11 , Gloria Ortega  3   12 , Alberto Titos-García  3   13 , Laura González-Sánchez  3   14 , Estíbalitz Pérez-Viejo  1   2   3 , Ángel Serrano  1   2   3 , Beatriz Martínez-Torres  1   2   3 , Regecop Group
Affiliations

Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)

Israel Manzanedo et al. J Clin Med. .

Abstract

Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in these diseases is complicated, since some of them are rare, so the analysis of large databases provides very valuable scientific information. The aim of this study is to analyze the global results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP), whose objective is to register all patients scheduled for HIPEC nationwide.

Methods: This is a retrospective analysis of the data recorded in the REGECOP from 36 Spanish hospitals from 2001 to 2021. There were 4159 surgical interventions in 3980 patients.

Results: 66% are women and 34% are men with a median age of 59 years (range 17-86). 41.5% of the patients were treated for Peritoneal Metastases (PM) of colorectal cancer (CRC); 32.4% were women with ovarian cancer (OC) with PM; 12.8% were treated for pseudomyxoma peritonei (PMP); 6.2% had PM from gastric cancer (GC); 4.9% had PM of non-conventional origin; and, finally, 2.1% of cases were patients diagnosed with peritoneal mesothelioma. The median Peritoneal Cancer Index (PCI) was 9 (0-39), and complete cytoreduction was achieved in 81.7% of the procedures. Severe morbidity (Dindo-Clavien grade III-IV) was observed in 17.7% of surgeries, with 2.1% mortality. Median hospital stay was 11 days (0-259). Median overall survival (OS) was 41 months for CRC patients, 55 months for women with OC, was not reached in PMP patients, was 14 months for GC patients, and 66 months in mesothelioma patients.

Conclusions: large databases provide extremely useful data. CRS with HIPEC in referral centers is a safe treatment with encouraging oncologic results in PSM.

Keywords: HIPEC; Peritoneal Surface Malignancies; cytoreductive surgery; peritoneal carcinomatosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The REGECOP is supported by COMBAT. Role of the funding source: support in data collection; the funders had no role in the design of the study, in the interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Overall survival of patients treated with cytoreductive surgery and HIPEC according to tumoral origin.
Figure 2
Figure 2
Overall Survival in colorectal cancer according to Peritoneal Cancer Index (PCI).
Figure 3
Figure 3
Overall survival in gastric cancer according to Peritoneal Cancer Index (PCI).
See this image and copyright information in PMC

References

    1. Brücher B.L., Piso P., Verwaal V., Esquivel J., Derraco M., Yonemura Y., Gonzalez-Moreno S., Pelz J., Königsrainer A., Ströhlein M., et al. Peritoneal carcinomatosis: Cytoreductive surgery and HIPEC—Overview and basics. Cancer Investig. 2012;30:209–224. doi: 10.3109/07357907.2012.654871. - DOI - PubMed
    1. Bhatt A., Glehen O. Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction. Ann. Surg. Oncol. 2020;27:1458–1470. doi: 10.1245/s10434-020-08208-z. - DOI - PubMed
    1. Yonemura Y., Canbay E., Li Y., Coccolini F., Glehen O., Sugarbaker P.H., Morris D., Moran B., Gonzaletz-Moreno S., Deraco M., et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur. J. Surg. Oncol. 2016;42:1123–1131. doi: 10.1016/j.ejso.2016.03.016. - DOI - PubMed
    1. Yan T.D., Welch L., Black D., Sugarbaker P.H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 2007;18:827–834. doi: 10.1093/annonc/mdl428. - DOI - PubMed
    1. Sugarbaker P.H. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76. doi: 10.1016/S1470-2045(05)70539-8. - DOI - PubMed

LinkOut - more resources